查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451195

2024-2032 年按药物类别、疾病类型、药物类型、配销通路和地区分類的忧郁症药物市场报告

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

2023年全球忧郁症药物市场规模达到186亿美元。展望未来， IMARC Group预计到2032年市场规模将达到246亿美元，2024-2032年复合年增长率（CAGR）为3.1%。

忧郁症是一种精神障碍，其特征是缺乏正面情绪、持续情绪低落以及众多认知、身体、行为和情绪症状。透过识别症状并检查患者的病史来诊断。然后使用忧郁症药物进行治疗，这种药物可以平衡大脑中血清素等神经传导物质的功能，并控制患者的情绪和情绪。这些药物可以帮助缓解焦虑、季节性情感障碍和心境恶劣的症状。

据世界卫生组织 (WHO) 称，忧郁症是导致残疾的主要原因之一，影响着全球超过 2.64 亿人。社交焦虑和忧郁等精神障碍的盛行率不断上升，是推动忧郁症药物市场成长的关键因素之一。此外，随着各国政府实施全面封锁并推动社交距离措施，很大一部分人口的日常生活发生了改变，进而对个人的心理健康产生了负面影响。这一趋势已成为促进忧郁症药物销售的另一个主要成长诱导因素。此外，随着新药物的接受度不断提高，用于开发副作用最小和长期效果的抗忧郁药物的新技术的出现，预计将推动未来几年的市场成长。

IMARC 集团的最新报告深入洞察了全球忧郁症药物市场，涵盖了其所有重要方面。内容涵盖从宏观市场概况到微观细节的行业表现、近期趋势、关键市场驱动因素和挑战、SWOT分析、波特五力分析、价值链分析等。该报告是行业参与者必读的内容，投资者、研究人员、顾问、商业策略家以及所有拥有任何利益或计划以任何方式进入忧郁症药物市场的人。

本报告回答的关键问题

  • 全球忧郁症药物市场有多大？
  • COVID-19 对全球忧郁症药物市场有何影响？
  • 全球忧郁症药物市场的预期成长率是多少？
  • 推动全球忧郁症药物市场的关键因素是什么？
  • 根据疾病类型，全球忧郁症药物市场的细分情况如何？
  • 全球忧郁症药物市场的配销通路划分如何？
  • 全球忧郁症药物市场的关键区域有哪些？
  • 全球忧郁症药物市场的主要公司/参与者有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球忧郁症药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场区隔：依药品类别
  • 市场区隔：按混乱类型
  • 市场区隔：依药物类型
  • 市场区隔：按配销通路
  • 市场区隔：按地区
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 非典型抗精神病药
    • 市场走向
    • 市场预测
  • 血清素-正肾上腺素再摄取抑制剂 (SNRI)
    • 市场走向
    • 市场预测
  • 选择性血清素再摄取抑制剂 (SSRI)
    • 市场走向
    • 市场预测
  • 中枢神经系统 (CNS) 兴奋剂
    • 市场走向
    • 市场预测
  • 三环抗忧郁药
    • 市场走向
    • 市场预测
  • 单胺氧化酶抑制剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依无序类型

  • 严重忧郁症
    • 市场走向
    • 市场预测
  • 强迫症
    • 市场走向
    • 市场预测
  • 广泛性焦虑症
    • 市场走向
    • 市场预测
  • 恐慌症
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依药物类型

  • 仿製药
    • 市场走向
    • 市场预测
  • 品牌药
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 市场走向
    • 市场预测
  • 欧洲
    • 市场走向
    • 市场预测
  • 亚太地区
    • 市场走向
    • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场预测
  • 拉丁美洲
    • 市场走向
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特的五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
Product Code: SR112024A1563

The global depression drugs market size reached US$ 18.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global depression drugs market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug class, disorder type, drug type and distribution channel.

Breakup by Drug Class:

Atypical Antipsychotics

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Selective Serotonin Reuptake Inhibitors (SSRIs)

Central Nervous System (CNS) Stimulants

Tricyclic Antidepressants

Monoamine Oxidase Inhibitors

Others

Breakup by Disorder Type:

Major Depressive Disorder

Obsessive-Compulsive Disorder

Generalized Anxiety Disorder

Panic Disorder

Others

Breakup by Drug Type:

Generic Drugs

Branded Drugs

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

  • 1. What is the size of the global depression drugs market?
  • 2. What has been the impact of COVID-19 on the global depression drugs market?
  • 3. What is the expected growth rate of the global depression drugs market?
  • 4. What are the key factors driving the global depression drugs market?
  • 5. What is the breakup of the global depression drugs market based on the disorder type?
  • 6. What is the breakup of the global depression drugs market based on the distribution channel?
  • 7. What are the key regions in the global depression drugs market?
  • 8. Who are the key companies/players in the global depression drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2023
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2024-2032
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players